Trial shows strong COVID protection in antibody combination

A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial.

Cornell Center for Health Equity offers racial allyship training

The Cornell Center for Health Equity has launched its racial allyship training course, providing anyone who wants to learn to be a better ally with essential skills and tools they can use in their personal and professional lives.

Archive cements female physicians into Weill Cornell history

Pauline Flaum-Dunoyer has interviewed more than a dozen women physicians of color, and donated the recordings and transcripts to NewYork-Presbyterian/Weill Cornell Medicine, where their legacies will be preserved for future generations.

Cornell Tech campus to name ‘Feeney Way’

There will soon be a second “Feeney Way” at Cornell: a central thoroughfare at Cornell Tech to be named in honor of the transformative impact and legacy of Charles F. “Chuck” Feeney ’56, the university’s most generous donor.

Cornell’s first Fashion Expo takes on New York City

The College of Human Ecology’s first Cornell Fashion Expo, held April 14, gave student designers a chance to present their work to industry experts and Cornell alumni in New York City, one of the fashion capitals of the world.

Cerebral blood vessels reveal potential stroke drug target

Strokes cause changes in gene activity in affected small blood vessels in the brain, changes that may be targetable with existing or future drugs to mitigate brain injury or improve stroke recovery, according to Weill Cornell Medicine scientists.

Edward Meyer ’49, Weill Cornell Medicine benefactor, dies

Edward H. Meyer ’49, a member of Weill Cornell Medicine’s Board of Fellows and devoted benefactor, died April 11 in New York, at age 96.

BioEntrepreneurship Initiative fosters entrepreneurial community

Members of the Cornell entrepreneurial community gathered to celebrate a successful first year of the BioEntrepreneurship Initiative at the program’s culminating workshop on March 18 in Midtown Manhattan.

Around Cornell

Organoids shown to speed glycoengineered vaccine development

Using a biomaterials-based organoid, a multi-institution team led by Matt DeLisa of Cornell Engineering was able to assess the strength of the immune response to a glycoengineered vaccine in days, instead of months.